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Characterization of Human Liver Stromal Cell Markers 
 
The liver is a highly immunologic, metabolic organ in the body with many functions 
including but not limited to amino acid and carbohydrate metabolism, synthesis of plasma proteins, 
metabolism of pharmaceuticals, defense against pathogens, and more. There are two types of 
stromal cells in the liver: liver sinusoidal endothelial cells and hepatic stellate cells. The goal of 
this thesis is to determine markers that can be used to identify human stromal cells. I investigated 
the expression of cellular surface and intracellular molecules on human stromal cells isolated from 
human livers. The cellular markers for this work in human samples were modeled after published 
data in mice. In order to test the stability of the expression of these markers in vitro, multiple 
stromal cell lines were generated from the human stromal cells, and different passage numbers of 
each cell line tested using flow cytometry. Phenotypic and morphological changes were found 
across multiple passage numbers where the stromal cells start to lose their strict structure. In 
addition to morphological changes, changes in expression of cellular markers were also identified. 
VCAM-1 (CD106) is changed across different passages and also reproduced across numerous cell 
lines. Cellular adhesion marker CD146 expression is also altered, and when coupled with antigen 
uptake of Ova via scavenger receptors on LSECs there is a strong shift in populations from single 
positive for each marker, scavenger receptor and CD146, to double positive across subsequent 
passages. Our identification of stromal cell markers can be used for further experiments for cellular 
sorting and functional studies of stromal cells.  
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Figures 
Figure 1.1: The Hepatic Sinusoid. The hepatic sinusoid is set up in a way that allows for all cell 
types to have interaction with the environment. The LSECs form a continuous lining of the liver 
sinusoids which separates the parenchymal, or fat storing cells, being the hepatic stellate cells. The 
LSECs lack a basement membrane and have open pores which help constitute the structure of the 
wall of the hepatic sinusoid. By allowing blood to pass from the sinusoid to the parenchyma, 
antigen uptake may occur. Kupffer cells also have direct access as the primary phagocytic cells in 
the environment. Dendritic cells are the sentinel cells surveying the microenvironment for 
pathogen. Hepatic Stellate Cells are known to live in the Space of Disse in between the hepatocytes 
and the endothelium which supports the LSECs having primary interaction with the blood and then 
the HSCs having secondary interaction. HSCs are also key players in regulation of blood flow due 
to their location and the size of the cells. (Figure is modified from Thomson and Knolle, Nature 
Reviews Immunology). !
 Figure 3.1: Growth rates between livers.   
(A)Growth rate between P0 and P1: This figure demonstrates the amount of time it took each 
sample to become confluent enough in the T25 Falcon flask to be split into a T75 Falcon flask (B).  
Growth rate between P1 and P2. After confluence was achieved in the T75 Falcon flask, the cells 
were split into a T175 Falcon flask as passage 2 (C). Growth from passage 2 to passage 3. The 
cells were split 1:2 from one T175 Falcon flask into two T175 Falcon flasks; average 5 days (D). 
Time between passages. Average time (days) from P0 to P1 is 19.43 days. Average time from P1 
to P2 average is 5 days. Average time from P2 to P3 is 5.31 days (D). 
Figure 3.2: Over subsequent passages the stromal cells showed morphological changes.  Images 
represent sequential passages for the stromal cells. Passage 1 has more cells growing close together 
(A). Passage 2 has cells that look very similar to passage 1; they look healthy and proliferate well (B). 
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Obvious cell morphology changes are seen in passage 8 (C). Cells lost structure and proliferative 
ability; this only worsens throughout the subsequent passages. Passage 14 has cells that have lost 
structure (D).   
Figure 3.3 Histograms showing positive and negative markers on Liver Sinusoidal Endothelial 
Cells. Representative histograms of positive markers include CD146 (A), scavenger receptor 
(OVA uptake (B), CD31 (C), CD54 (D), MHC I (G), MHC II (H), CD80 (I), and CD106 (K). 
Negative results, or very lowly expressed markers include CD32 (E), CD50 (F), CD86 (J), and 
CD206 (L). Each panel includes unstained, isotype control, passage 5 (red), passage 7 (cyan), and 
passage 9 (green) except from OVA (B). Isotype control not applicable for OVA uptake. 
Figure 3.4 Mean Fluorescence Intensity (MFI) of markers on Liver Sinusoidal Endothelial 
Cells. The statistical data from figure 3.3 are represented and quantified here. Each marker and its 
respective MFI was quantified to show which marker is expressed and to what degree. All markers 
were tested with an isotype control (grey). Each bar graph includes unstained, isotype control, 
passage 5 (red), passage 7 (cyan), and passage 9 (green) except from OVA (B. Isotype control not 
applicable for OVA uptake; unstained included for OVA.  
Figure 3.5 Hepatic Stellate Cells marker identification can be seen across different passage 
numbers. Representative histograms of the markers that were investigated for hepatic stellate 
cells. CD14 is seen as a positive marker (A) as is Vimentin (B) and only one sample for α-SMA 
(C, far right). Podoplanin (G) also has high levels of positive expression. Negative expression can 
be seen in GFAP (D) and three of four samples in CD38 (E).  
Figure 3.6 Mean Fluorescence Intensity (MFI) of Hepatic Stellate Cells. Statistical data of 
figure 3.5 are shown with the MFI data. MFI is quantified to show which marker is expressed and 
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to what degree. All markers were tested with an unstained control and an isotype control (grey). 
Each bar graph includes isotype control, passage 5 (red), passage 7 (cyan), and passage 9 (green). 
Positive expression is seen in HSC activation marker CD14 (A), intracellular stain for Vimentin 
(B), and podoplanin (F). Negative expression is seen in CD38 (D), very low expression is seen in 
Desmin (E).  
Figure 3.7 Population shift in CD146+ OVA+ cells across passages. Representation of contour plots 
show dramatic shifts in cellular populations for CD146+ OVA+ cells across different passages that 
include passage 5, passage 7, and passage 9 for human liver sample digested on 8/17/16 (A, left to 
right). The cellular population shift between a low population of CD146+ OVA+ for passage 5 
increases in different samples as well, this can be represented in human liver sample 12-21-16 (B, left 
to right). The shift in population can be seen in samples that have either not undergone chemotherapy 
treatment and those that have (A and B). 
Figure 3.8: In order to fully understand how the population has shifted, MFI from figure 3.7 was 
calculated for each sample, for OVA, CD146 and CD146 expression compared to Isotype (A and B). 
8/17/16 (A). 12/21/16 (B).  While the OVA population didn’t increase as dramatically as expected (A 
and B left), CD146 MFI increased drastically across passage numbers (A and B, right). The total 
number of cells that presented with this double positive population increased across passage numbers 
and is shown as a frequency of total bar graph (C). 
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Tables 
Table 1.1: Table 1.1 List of Liver Sinusoidal Endothelial Cell Surface Markers that were 
tested. Table indicates markers previously tested in mice. All cell markers listed are surface 
markers. 
Table 1.2: List of Hepatic Stellate Cell markers; Surface and Intracellular. *intracellular 
markers 
Table 1.3 (Appendix):  Human tissue sample data and observation allow for characterization 
of disease and origin of sample. The quantification of data that is acquired from these samples 
informs experimental design based on selection of patient populations; i.e. male vs female 
experiments, similar diagnosis, chemotherapy treatment and other options. *patient underwent 
chemotherapy **patient underwent radiation treatment 
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Chapter 1: Background 
1.1 Introduction:  
The liver is a highly immunologic organ with the power to possess many different functions 
that may impact the whole body. The liver is the body’s largest internal organ that is responsible 
for glycogen synthesis, bile production, processing food, amino acid and carbohydrate metabolism, 
synthesis of plasma proteins, metabolism of pharmaceuticals, defense against pathogens, oral 
tolerance, and other functions. With all of these abilities it is no wonder that this organ is vital to 
maintenance of life and why many of the interactions that take place in the liver are translatable. 
The liver sits just above the stomach in the body cavity and allows for an ease of access of food 
antigens to be recognized via gut transport and thus oral tolerance. The identification of oral 
tolerance in the body is highly important because it allows for a nonresponse to innocuous food 
antigens. This will facilitate digestion rather than provoking an immune response when the body 
does not need to have one.  
The liver is such a vital organ that, when damaged by disease, the consequences can be 
detrimental to the body. There is interest in the use of liver stromal cells for therapy. A number of 
studies have investigated how stromal cells impact diseases including but not limited to hepatitis, 
cirrhosis, cancers, medicinal damage, fibrosis, inflammatory liver diseases, and others. This is 
incredibly important work since over one million Americans alone are infected with Hepatitis B, 
over four million Americans are infected with Hepatitis C, 21,000 Americans are diagnosed every 
year with liver cancer, and on average 20% of Americans have fatty livers (American Liver 
Foundation, 2013). These diseases can cause cirrhosis and ultimately liver failure if not recognized 
and treated. Liver disease is on the rise as the fourth leading cause of death in the United States 
alone. Importantly, liver disease is increasing in children; over six million, have been diagnosed 
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with non-alcoholic fatty liver disease. While these statistics are incredibly alarming, hopefully with 
the understanding of how stromal cells interact in the liver with neighboring cells; resident and 
infiltrating, and how progression of disease occurs, there can advances in diagnosis and treatment 
of liver disease.   
Stromal cells may actually be used therapeutically if able to be controlled. While stromal 
cells have positive features such as forming connective tissue, stromal cells also can have very 
negative effects when they are uncontrolled and can lead to fibrosis because of the excessive 
amount of collagen that is produced from stellate cells under liver injury. The excessive amount 
of collagen leads to scar tissue and ultimately cirrhosis and liver failure.  
While liver stromal cells perform important work that impacts the entire organ, they only 
are a small percentage of cells in the organ. General make up of the liver is approximately 80% 
hepatocytes and the other 20% comprises a mixture of many other key players such as Kupffer 
cells, Liver Sinusoidal Endothelial Cells (LSEC), Hepatic Stellate Cells (HSC), T cells, 
Macrophages, and Antigen Presenting Cells such as Dendritic Cells. Figure 1.1 represents a 
microscopic depiction of the hepatic sinusoid which has both of the stromal cell subsets identified 
as well as the other cells that make up the liver such as Kupffer cells, T cells and Dendritic cells. 
These cells live in the sinusoid where the smaller, flat HSCs are found in the space of Disse. In 
addition to the HSCs being resident in the space of Disse, the microvilli of the hepatocytes extend 
out and uptake proteins here which are seen in Figure 1.1 which illustrates the complexity of the 
sinusoid and how each cell performs specific duties to maintain proper function. The make up of 
the liver sinusoid is complex but the identification of each cell type allows for further investigation 
into the cell-cell interactions in the organ and what role each cell plays.  
3 
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Figure 1.1: The Hepatic Sinusoid. The hepatic sinusoid is set up in a way that allows for all cell types to have 
interaction with the environment. The LSECs form a continuous lining of the liver sinusoids which separates the 
parenchymal, or fat storing cells, being the hepatic stellate cells. The LSECs lack a basement membrane and have 
open pores which help constitute the structure of the wall of the hepatic sinusoid. By allowing blood to pass from the 
sinusoid to the parenchyma, antigen uptake may occur. Kupffer cells also have direct access as the primary phagocytic 
cells in the environment. Dendritic cells are the sentinel cells surveying the microenvironment for pathogen. Hepatic 
Stellate Cells are known to live in the Space of Disse in between the hepatocytes and the endothelium which supports 
the LSECs having primary interaction with the blood and then the HSCs having secondary interaction. HSCs are also 
key players in regulation of blood flow due to their location and the size of the cells. (Figure is modified from Thomson 
and Knolle, Nature Reviews Immunology). !
The cellular subset of primary investigation in this project are the liver stromal cells. By 
definition stromal cells are and comprise the connective tissue of any organ including the lymph 
node, kidney, liver, and so on. Beyond being a connective tissue source in the body, stromal cells 
also support the function of many other cells in the body such as mesenchymal and parenchymal 
cells. Parenchymal cells, such as hepatocytes, are functional cells and mesenchymal cells are 
structural cells. Mesenchymal cells differentiate into many different structural cells such as stromal 
cells, osteoblasts, chondrocytes, and stromal cells. Studying stromal cells has led to understanding 
of their importance as a cellular subset and how differentiation may treat disease including cancers 
and cardiovascular disease by bone marrow derived mesenchymal stromal cells (BMDC) 
(Copland, 2011). BMDCs are especially useful in treatment of Sickle Cell Disease in that BMDCs 
are thought to help prevent Graft Versus Host Disease after transplantation because of the 
immunoregulatory properties that BMDCs possess; such as upregulation of MHC II under 
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inflammatory conditions which may help to stop rejection of transplants (Stenger, 2017). These 
examples demonstrate the necessity for stromal cells and their function. Beyond being a mediator 
in disease, stromal cells are also very versatile and have many capabilities across the body such as 
the creation of bone, cartilage, lymph nodes, and liver. There are many different types of stromal 
cells in the body, however HSC and LSEC are the two subsets in the liver. These two subsets have 
very different purposes in the liver including but not limited to; LSEC’s having the ability to be 
immune surveyors and when activated HSC can produce collagen. When collagen production is 
not moderated, fibrosis and cirrhosis occur. The maintenance of cellular homeostasis is key in the 
liver and HSCs and LSECs are important regulators of liver homeostasis. 
1.2 Liver sinusoidal endothelial cells 
Liver Sinusoidal Endothelial Cells (LSEC) have a controversial history. Many individuals 
in the field didn’t distinguish these cells as a distinct cell type until approximately 1978 when 
Eddie Wisse became the leading LSEC investigator. LSECs as a cell type have very unique 
properties such as possessing large amounts of endocytic vesicles. These vesicles and endocytic 
ability show the dynamics of LSECs and how they are so vitally important in antigen uptake via 
scavenger receptors on the cellular surface which surveys blood passing into the parenchyma 
through the sinusoids in the liver (Friedman, 2008). Although they possess the ability to perform 
antigen uptake, LSECs do not typically take up very large particles; that is reserved for the role of 
the Kupffer cells. A major difference between these two cell types is that LSECs aren’t typically 
the phagocytic cells, the Kupffer cells are (Kawai, 2001). When the ability of the Kupffer cells is 
compromised, then the LSECs take on the role of being the phagocytic cell type which enables 
them to uptake particles up to 1 µm in size. LSECs play a role in liver homeostasis via the 
scavenger receptor system, allowing the LSECs to clear foreign antigen from circulation 
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(Evlvevold et al., 2008, Schurich, 2009). In addition to antigen uptake, LSECs also have major 
roles in blood flow in the body and directing the drainage from the lymphatic in the space of Disse. 
This also aids in the ability to uptake antigen and perform other immune functions. Beyond being 
surveyors of the immune system, LSECs have powerful capabilities in controlling inflammatory 
immune responses because LSECs have the ability to induce regulatory T cells by secreting TGFβ 
which stimulates and primes regulatory T cells (Schildberg, 2015). LSECs also have very powerful 
abilities to cross prime naïve CD8 T cells and act as surveyors of the environment for microbial 
infections (Knolle, 2016). The LSECs uptake circulating antigen and present said antigen to CD8 
T cells via MHC class I ligand. This process shows the interaction these cells have with 
neighboring cells and how versatile the LSEC population can be. In addition, LSECs have 
capabilities to interact with activated T cells by virtue of the LSECtin ligand which binds to LAG-
3 and CD44. LSECtin interaction with LAG-3 restores interferon gamma secretion in cases of 
melanoma (Xu, 2014) and LSECtin interaction with CD44 is an incredibly important function of 
LSECs because this gives the cells the ability to inhibit T cell activation, which will dampen 
immune responses and/or induce apoptosis. When this process is defective, autoimmunity in the 
liver develops. Therefore, LSECs are instrumental in maintenance and control of autoimmunity by 
activated T cells. Lastly, LSECs also have the ability to interact with resident antigen presenting 
cells in the liver. This collaborative effort between of LSECs and dendritic cells can suppress 
dendritic cell priming of naïve T cells (Schildberg, 2015). Thus LSECs are instrumental to 
maintaining liver homeostasis while serving as immune surveyors via the scavenger receptor 
system (Braet, 2002).  
1.3 Hepatic Stellate Cells 
6 
!
Hepatic Stellate Cells (HSC) are a peri-sinusoidal cell type which resides in the space of Disse 
in the liver. The HSCs have a special anatomy in that they span the circumference of the liver 
sinusoids and thus help in the maintenance and control of blood flow through the sinusoid which 
is mediated by contraction and reduction of the sinusoid (Knolle, 2016). Beyond having structural 
differences from LSECs, the HSCs have a specialized storage mechanism for Vitamin A. These 
cells have vesicles, both extracellular and intracellular for vitamin A storage. These cells represent 
the main storage for vitamin A in the body. Balance and storage of Vitamin A s important to the 
maintenance of teeth, soft tissue, skeletal tissue, mucus membranes and skin. When HSCs undergo 
activation, they lose the quiescent vitamin A storage and are pushed into an activated state which 
causes their proliferation. When HSCs become activated, they produce collagen; when this is 
produced in excess it can lead to cirrhosis. In addition to excessive collagen production, HSCs can 
become suppressive during fibrosis, which occurs from a secretion of inhibitory cytokines such as 
IL-10 and TGFβ after the HSCs have become activated (Schildberg, 2015). The activation of HSCs 
may be achieved by a number of different mechanisms such as loss of IL-10, activation by reactive 
oxygen species produced by Kupffer cells, inflammatory conditions (Rifaat, 2002). Therefore, the 
biological capabilities of HSCs are vastly different from LSECs in that HSCs have the ability to 
be a major benefit in the body with Vitamin A or a detriment, by producing excessive collagen 
potentially leading to cirrhosis.  
1.4 Cellular Markers   
Markers for mouse LSEC and HSC have been published. CD146 is expressed on 
endothelial cells, including LSECs and is important in supporting endothelial integrity (Schrange, 
2008), as well as antigen uptake via scavenger receptors, demonstrated by OVA uptake (Limmer, 
2000). CD45 is a marker used to exclude leukocytes and included to ensure specificity of the 
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subsets (LSEC and HSC) that were tested (Table 1.1). Other molecules expressed on LSECs 
include costimulatory molecules CD80 and CD86, MHC I and MHC II, as well as CD50 (ICAM-
3) and CD54 (ICAM-1). CD106 (VCAM-1) expression on LSECs has been questionable. 
Activated hepatic stellate cells express CD14, α-SMA, Vimentin, and Desmin (Table 1.2). GFAP 
should be expressed in quiescent cells but GFAP expression is lost. CD38 is constitutively 
expressed in both in vitro and in vivo experiments of HSC (March, 2007). As stated previously, 
the markers that were tested for both cellular subsets; LSEC and HSC, were of those that had been 
previously characterized in mice which did include a finding of constitutive  
 expression by express MHC I, MHC II, CD80 and CD86 (Schurich, 2009). We examined the  
expression of all of these molecules on human stromal cells (Table1.1, 1.2). 
1.5 Human patients  
 Samples were acquired through a collaborative effort between Massachusetts General 
Hospital (MGH), the Ragon Institute, and Harvard Medical School. The samples were all deemed 
healthy tissue by the pathologists and doctors at MGH because the patients and samples resected 
didn’t have a viral infection such as HIV, HCV, HPV or inflammatory liver diseases. The majority 
of patients presented with cancer of different forms including choloangiocarcinoma, colon cancer, 
metastatic renal cell carcinoma (Appendix, Table 1.3). The pathologists assured us the samples 
were taken at least 2 cm away from where the tumor presented in the liver. Size of samples varied 
as well as ease of digestibility of each sample (Appendix, Table 1.3). 7 out of 18 samples were 
from patients who had undergone chemotherapy treatment and one sample was from a patient who 
had radiation therapy, which adds another layer of complexity to the samples that were acquired. 
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 Table 1.1 List of Surface Markers that were tested in Human Liver Sinusoidal Endothelial Cells. Table lists 
markers that were previously tested in mice. All cell markers listed are surface markers.  
 
 
Marker HSC Function Clone Company 
VIMENTIN * HSC Maintenance of cellular shape; major 
protein of mesenchymal cells 
2D1 Antibodies online 
CD14 HSC Hepatic Stellate Cell activation marker Monoclonal 
(HVimentin) 
Biolegend 
CD38 HSC Cyclic ADP ribose hydrolase, present 
on surface of immune cells 
HB-7 Biolegend 
ALPHA-SMA* HSC Actin isoform, stellate cell activation 17H19L35 ThermoFisher Scientific 
GFAP* HSC Stellate cell activation REA335 miltenyibiotech 
DESMIN* HSC Stellate cell identification IgG1 Monoclonal 
[4G1] 
Lifespan Biosciences, Inc. 
PODOPLANIN HSC Mucin-type protein NO-08 Biolegend 
ZOMBIE NIR  Live/Dead identification  ThermoFisher Scientific 
Table 1.2 List of Hepatic Stellate Cell markers; Surface and Intracellular. *intracellular markers  
  
Marker LSEC Function Clone  Company 
CD146 LSEC Melanoma cell adhesion molecule (MCAM), marker for 
endothelial cell lineage 
P1H12 (PE) 
(PerCP/Cy5.5) 
Biolegend 
CD31 LSEC Platelet endothelial cell adhesion molecule (PECAM-1), 
removing aged neutrophils from body 
WM59 Biolegend 
CD45  Leukocyte exclusion H130 Biolegend 
CD106 LSEC Vascular Cell Adhesion Molecule-1, Leukocyte-
endothelial cell adhesion 
429MVCAM.A Biolegend 
CD50 LSEC Intracellular Adhesion molecule 3; signaling molecule CBR-IC3/1 eBioscience 
ALEXA-
647 OVA 
LSEC Scavenger receptor uptake and presentation  ThermoFisher 
Scientific 
LYVE-1 LSEC Lymphatic Vessel Endothelial Receptor 1, transmembrane 
receptor for extracellular matrix glycosaminoglycan HA 
OAAB21889 Aviva systems 
Biology 
MHC I LSEC Bind peptide fragments from proteins and display them on 
the cellular surface for T cell recognition 
TU36 Biolegend 
MHC II LSEC Antigen presentation from exogenous sources primarily to 
CD4+ T cells 
W6/32 Biolegend 
CD80 LSEC B7-1; costimulatory signal required for T cell activation 2D10 Biolegend 
CD86 LSEC B7-2; costimulatory signal required for T cell activation BU63 ThermoFisher 
Scientific 
CD32 LSEC IgG Fc receptor; most abundantly distributed in human 
body, expressed on myeloid and lymphoid cells 
FUN-2 Biolegend 
CD206 LSEC Mannose Receptor, C-type lectin MMR 15-2 Biolegend 
CD54 LSEC Intracellular Adhesion Molecule – 1, signaling molecule  Biorbyt 
ZOMBIE 
NIR 
 Live/Dead identification  ThermoFisher 
Sientific 
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1.6 Questions Addressed in this Thesis  
In this thesis, we sought to identify cellular markers, surface or intracellular, for human 
liver stromal cells (Hepatic Stellate Cells or Liver Sinusoidal Endothelial Cells). Characterization 
of stromal cells in human samples has been limited; this thesis hopefully will provide a better 
understanding of the markers that can be detected on human liver stromal cells. Markers defined 
on mouse liver stromal cells served as a useful benchmark for comparison and inspiration for our 
human project. We first examined markers expressed by mouse stromal cells in our experiments 
with human samples to determine what markers are present and to what degree. We also 
investigated how human stromal cells grow in culture and compared stromal cells at different 
passage numbers for expression of markers and their integrity. We have determined stromal cell 
growth patterns and identified some stromal cell markers for human Hepatic Stellate Cells and 
Liver Sinusoidal Endothelial Cells.  
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Chapter 2: Materials and Methods 
Section 2:1: Tissue digestion. Human samples were obtained through a collaboration between 
The Ragon Institution, Harvard Medical School and the Massachusetts General Hospital surgical 
department. Each sample obtained from patients was qualified as healthy unless documented 
otherwise by hospital specialists. Documentation of treatment, therapy, medication and other 
variables in the samples were recorded for research purposes as well. Tissues obtained from 
patients with cancers have resections taken approximately 2 cm away from the tumor. Samples 
from patients that had undergone chemotherapy or radiation were documented and were digested 
using the same protocol as the other samples to create a standardized protocol. Samples were 
digested using a solution of 15mL PBS +/+ (Invitrogen), DNAse (Akron Biotech), and 
Collagenase (Worthington Biochemical) to form a digestion buffer kept at 37 °C. Samples were 
cut into as small of pieces as possible to allow for adequate digestion and placed into the digestion 
buffer for 20 minutes at 37 °C. This time was to allow for sufficient digestion of the sample. 
Samples were mixed once at 10 minutes. Samples were passed through a metal strainer in order to 
completely dissociate the tissue, separate out the cells from fat, and complete the digestion process. 
Next, cells were transferred into at 50 mL Falcon Conical tube and spun in the centrifuge at 1800 
g for 5 minutes. Cells were then washed two times with phosphate buffered saline (PBS, 
Invitrogen) and spun at 1800 G for 5 minutes during each washing step. The supernatant was 
aspirated carefully from the conical after each spin while the pellet of cells remained at the bottom 
of the conical tube. The cells were then resuspended in 5 mL of the ALPHA MEM, + L-Glutamine, 
-Deoxyribo, -Ribonucleodite (Life Technologies), 30% fetal bovine serum (FBS) (Sigma), 1 % 
penicillin- streptomycin (100 U penicillin and 100 µg streptomycin (Invitrogen)), and plated into 
a T25 Falcon Flask and immediately placed in a 5% CO2 incubator at 37 °C. 
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Section 2.2: Cell Culture: Each cell line was maintained for many passage numbers to help 
understand longevity of the cells and compare growth rates and stability of the cell lines across 
different passages. As each liver was from a different donor, each has a different profile of 
digestion aspects, growth rates, resiliency, longevity, and ability to withstand dissociation using 
0.05% Trypsin (ThermoFisher Scientific). Cells were maintained using in ALPHA MEM, + L-
Glutamine, -Deoxyribo, -Ribonucleodite (Life Technologies). To make the media complete, one 
bottle of 500 mL ALPHA MEM, + L-Glutamine, -Deoxyribo, -Ribonucleodite (Live 
Technologies) was used plus 30% FBS (Sigma) and 1% penicillin- streptomycin (Invitrogen), to 
be called ALPHA MEM complete. One of the most important aspects for cellular maintenance 
was not only changing the media immediately the next day following the digestion process, but 
was also changing the media a second day in a row for those cells in the T25 Falcon Flask. This 
step became important for removing the remaining fat cells and dead cells from the stromal cells 
to give optimal nutrients to the cells that were growing. When cells became confluent across the 
T25 at approximately 19 days, the cells were dissociated using 0.05% Trypsin (ThermoScientific). 
10 mL of ALPHA MEM, + L-Glutamine, -Deoxyribo, -Ribonucleodite (Life Technologies), 30% 
FBS (Sigma), 1 % penicillin- streptomycin (100 U penicillin and 100 µg streptomycin 
(Invitrogen)), was added to neutralize the 0.05% Trypsin (ThermoFisher Scientific). Cells were 
spun at 1800 g for 5 minutes in the centrifuge. Supernatant was aspirated off and cells were 
resuspended in 15 mL of ALPHA MEM complete media and plated into a T75 Falcon Flask. When 
cells became confluent across the T75 at approximately 5 days, the cells were dissociated  and 
washed as described above, and resuspended in 15 mL of ALPHA MEM, + L-Glutamine, -
Deoxyribo, -Ribonucleodite (Life Technologies), 30% FBS (Sigma), 1 % penicillin- streptomycin 
(100 U penicillin and 100 µg streptomycin (Invitrogen)) media and plated into a T175 Falcon 
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Flask. Each flask was subsequently split at 1:2 in order to keep enough cells in the flask to allow 
for differentiation and proliferation. 1:3 proved too sparse for the cells to grow very well.  
Section 2:3 Cell Freezing: Flasks with stromal cells used for freezing were first washed with 
PBS-/- (Invitrogen) to help with dead cell clearance and then trypsinized using 5 mL of trypsin 
(ThermoFisher Scientific) placed into the flask for approximately 1.5 minutes to allow for cells to 
be detached from the flask. 10 mL of ALPHA MEM, + L-Glutamine, -Deoxyribo, -Ribonucleodite 
(Life Technologies), 30% FBS (Sigma), 1% penicillin- streptomycin (Invitrogen) mixture was 
added to the flask to neutralize the trypsin (ThermoFisher Scientific). Cells were collected and 
transferred to a 50 mL conical and spun at 1800 G for 5 minutes to form a pellet. The 
Trypsin/media mixture was aspirated, and Cells were resuspended in the same media, Flasks that 
were frozen down in cryovials were frozen in a 2 cryovials to 1 flask ratio. Cells to be frozen were 
resuspended in a 500 µL per cryovials of the ALPHA MEM complete and 500 µL of the freezing 
media (8mL FBS (Sigma) + 2ML DMSO (Sigma)) per every ! flask. Once the Freezing media 
(8mL FBS (Sigma) + 2ML DMSO (Sigma)) were added to the cryovials with the cell mixture, 
they were immediately placed on ice in a Mr. Frosty cooling chamber to be placed in the freezer. 
The chamber cools the cells at 1 °C per hour to not lose as many cells to freezing procedures. Mr. 
Frosty was placed in the -80 °C freezer for 24 hours and cells in cryovials were then transferred 
into liquid nitrogen for long term storage.  
Section 2:4 Thawing of cells: Cryovials that were placed in the liquid nitrogen must be thawed 
with the utmost care due to the cytotoxic effect of DMSO (Sigma) on the cells. Vials were thawed 
using a water bath at 37 °C to bring them to room temperature quickly. Vials were thawed to 
approximately 75% and then the contents added to ALPHA MEM complete media that had been 
warmed to 37 °C. The DMSO (Sigma) mixture was replaced with the media mixture mentioned 
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above to keep as many cells as possible alive. Media in the flask was changed the next day in order 
to ensure that any remaining DMSO (Sigma) had been aspirated off and to provide for adequate 
nutrients.  
Section 2.5: Flow Cytometry: Surface marker and intracellular staining of cellular markers was 
performed in the dark at 4°C.. MACS buffer (1% FBS (Sigma), PBS -/- (Invitrogen), 2mM EDTA 
(Invitrogen)) was used to maintain cells during the procedure. Table 1.1 lists the antibodies, clone, 
and company from which they were purchased. Cells were plated in 96 well plates in order to have 
a more standardized procedure for use with the multichannel pipet. The multichannel pipet made 
the measurements more accurate and time required for staining shorter. Surface markers, Fc block, 
Live/Dead staining were all incubated for 20 minutes at 4°C. Surface markers were stained at a 
1:200 dilution of antibody to MACS buffer at 4°C and Live/Dead stain was used at a 1:1000 
dilution to MACS buffer. Intracellular staining was accomplished using the eBioscience 
intracellular staining kit after the completion of surface marker staining. 200 µL of IC Fixation 
Buffer (eBioscience) was added to each well and incubated on ice and protected from light for 30 
minutes at 4°C. Cells were then spun for 2 minutes at 2280 g. 200 µL of 1X permeabilization 
buffer (eBioscience) was added to each well and spun for 5 minutes, supernatant was discarded 
and repeated. Cells were then resuspended in 100 µL of 1X permeabilization buffer (eBioscience). 
Intracellular antibodies were added to each well at a 1:200 concentration and incubated on ice, 
protected from light for 30 minutes. Cells were spun at 1900 RPM for 2 minutes, supernatant 
discarded. The cells were resuspended in 200 µL of the MACS buffer and spun at 1900 RPM for 
2 minutes. Supernatant was discarded and cells were resuspended in 200 µL of permeabilization 
buffer to which the secondary antibody was added at a 1:200 concentration and incubated on ice 
with protection from light for 20 minutes at 4°C. Cells were spun at 1900 RPM for 2 minutes, 
14 
!
supernatant was discarded and cells were resuspended in 2000 µL of permeabilization buffer. Cells 
were spun at 1900 RPM for 2 minutes, supernatant was aspirated and discarded. Cells were 
resuspended in 200 µL of MACS buffer. Flow cytometry was performed using the LSR II 
instrument from BD Biosciences and data c analyzed using FlowJo v10.1 (FlowJo, LLC).   
Section 2.6: Statistical Analysis. Statistical analysis was completed using Prism.  
  
15 
!
Chapter 3: Results 
Section 3.1: Human samples vary as far as size, digestion process, and growth rate. Samples 
that were acquired for digestion ranged in size, color, appearance; some presented with white 
nodules, some had very red spots on them, certain samples had darker coloring, some had excessive 
amounts of fat, and each was different from the next. Some tissues sizes were much larger than 
others and some samples had much more fat remaining after the digestion process had been 
completed (Appendix, Table 1.3). Certain tissue samples were much tougher regarding digestion 
than others which could have been due to fibrosis or other factors. Although the patients presented 
with different backgrounds, the most common reason for resection was due to a 
choloangiocarcinoma diagnosis. All samples were negative for viruses including HIV, HPV, HCV. 
Most patients were female and ranged from 55 years of age to 82 years of age (Appendix, Table 
1.3). Not only did the samples present very differently visually and differ in digestion, but the 
sample growth patterns varied greatly as well. Stromal cells grew very slowly from the initial 
digestion to confluence in the original T25 flask (Figure 3.1). The first passage occurred at day 19 
on average and cell passaging became a much quicker process after the cells started to grow. 
Approximately 5 days after the original passage into a T75 flask the cells were then ready to be 
split into a T175 (Figure 3.1). This became an average benchmark for how often the cells needed 
to be passaged.  
While the cells grew very well together, the morphology of the cells changed as the passage 
numbers got higher in that the cells became looser cells and didn’t maintain structure While this 
is a very interesting finding, unfortunately, there was not a specific passage number where this 
occurred; it was different for every sample. Some samples started to lose their morphology at 
passage 8 and others lost their stringent morphology at passage 14 (Figure 3.2). 
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3.2 Identification of markers for Liver Sinusoidal Endothelial Cells. Based on previously 
published data identifying markers for LSEC in mice. we selected the markers to test on human 
samples (Friedman, Knolle, Schildberg). We explored CD146, CD31, scavenger receptor which is 
represented by OVA, mannose receptor, CD32, MHC I, MHC II, costimulatory receptors CD80 
and CD86. In order to fully understand the stability of these markers, we compared their expression 
in cell lines over several passages. Passage numbers  tested were passage 5, passage 7, and passage 
9. (Figure 3.3).  
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
0
10
20
30
40
Time from P0 to P1
Donor 
Da
ys
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
0
5
10
15
Time from P2 to P3
Donor
Da
ys
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
0
5
10
15
Time from P1 to P2
Donor
Da
ys
P1 P2 P3
0
10
20
30
Time between passages
Passage number
Da
ys
P1
P2
P3
Figure 3.1: Growth rates between livers.   
(A)Growth rate between P0 and P1: This figure demonstrates the amount of time it took each sample to become confluent 
enough in the T25 Falcon flask to be split into a T75 Falcon flask (B).  Growth rate between P1 and P2. After confluence 
was achieved in the T75 Falcon flask, the cells were split into a T175 Falcon flask as passage 2 (C). Growth from passage 
2 to passage 3. The cells were split 1:2 from one T175 Falcon flask into two T175 Falcon flasks; average 5 days (D). 
Time between passages. Average time (days) from P0 to P1 is 19.43 days. Average time from P1 to P2 average is 5 days. 
Average time from P2 to P3 is 5.31 days (D).  
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Figure 3.2: Over subsequent passages the stromal cells showed morphological changes.  Images represent sequential 
passages for the stromal cells. Passage 1 has more cells growing close together (A). Passage 2 has cells that look very similar 
to passage 1; they look healthy and proliferate well (B). Obvious cell morphology changes are seen in passage 8 (C). Cells 
lost structure and proliferative ability; this only worsens throughout the subsequent passages. Passage 14 has cells that have 
lost structure (D).   
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Figure 3.3 Histograms showing positive and negative markers on Liver Sinusoidal Endothelial Cells. Representative 
histograms of positive markers include CD146 (A), scavenger receptor (OVA uptake (B), CD31 (C), CD54 (D), MHC 
I (G), MHC II (H), CD80 (I), and CD106 (K). Negative results, or very lowly expressed markers include CD32 (E), 
CD50 (F), CD86 (J), and CD206 (L). Each panel includes unstained, isotype control, passage 5 (red), passage 7 
(cyan), and passage 9 (green) except from OVA (B). Isotype control not applicable for OVA uptake.  
Three passage numbers were picked as different time points; early passage number, 5, a middle 
passage, 7, and a late passage number, 9. We tested these samples at different passage numbers to 
understand how stable the markers are and to what degree the markers are still present at later 
pasage numbers versus earlier passage numbers. Mean Fluorescence Intensity (MFI) was also 
calculated in order to have a more quantifiable parameter for the level of LSEC marker 
identification (Figure 3.4). We identified CD146, CD106, MHC I, MHC II, CD80, and CD54 as 
markers that were expressed. We included controls of an unstained sample in each experiment, 
and a single color control in order to have an individual stain for the marker, the comparison 
between many passages (5, 7, 9), and lastly an isotype control. The isotype control was included 
to serve as a negative control in comparison to our single stain for a postive control.  
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The expression level on the positive samples varied which added another layer of compexicity. 
CD146 was present in all samples but at a different level in each. This was true for OVA uptake 
as well.. CD54 expression was clear on populations in three of four  samples but had vastly 
Figure 3.4 Mean Fluorescence Intensity (MFI) of markers on Liver Sinusoidal Endothelial Cells. The 
statistical data from figure 3.3 are represented and quantified here. Each marker and its respective MFI was 
quantified to show which marker is expressed and to what degree. All markers were tested with an isotype control 
(grey). Each bar graph includes unstained, isotype control, passage 5 (red), passage 7 (cyan), and passage 9 (green) 
except from OVA (B. Isotype control not applicable for OVA uptake; unstained included for OVA.  
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different flourscence intensities (Figure 3.4,!D). These findings show the variability of the samples 
that were tested and illustrate the complexity of the project. CD32, CD50, CD86, and CD206  were 
not expressed on LSECs (Figure 3.4, E, F, J, L). These are seen as negative because of the lack 
of signal in the histograms in comparison to both the unstained control and the isotype control.  
3.3 Identification of cellular markers for Hepatic Stellate Cell. The other stromal cellular subset 
that was explored, HSCs Mouse HSC had a set of markers that differentiated them from the LSECs. 
Mouse HSCs had Vitamin A, CD14, Vimentin, Desmin, GFAP and podoplanin. These cell 
markers were primarily intracellular markers (GFAP, Desmin, α-SMA, and Vimentin); however, 
certain surface markers were expressed including CD38, podoplanin, and CD14 s (Weiskirchen, 
2014). Vitamin A is a defining characteristic for mouse liver stellate cells and is known to glow in 
UV light. Both the BV510 and FITC channel on the LSR II were both kept open to hopefully detect 
a positive signal in those channels which would indicate stellate cells due to the glowing of the 
Vitamin A in the UV light, however no signal was observed in any of our samples tested. The 
design was much the same as in the LSEC experiments. Each representative histogram contains 
the unstained control, isotype control, passage 5, passage 7, and passage 9 just as was shown 
previously (Figure 3.5). We found that Vimentin was expressed across passage numbers (Figure 
3.5). Thus we found that what was known in about vimentin expression in HSCs in mice translated 
to human HSCs, (Uyama, 2006). Histograms are represented across different passages, 5, 7, and 9 
just as in figure 3.3. These findings identify positive expression of Vimentin, α-SMA, CD14, and 
Podoplanin for HSCs and negative expression of GFAP, Desmin, and low expression of CD38.  
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Figure 3.5 Hepatic Stellate Cells marker identification can be seen across different passage numbers. 
Representative histograms of the markers that were investigated for hepatic stellate cells. CD14 is seen as a positive 
marker (A) as is Vimentin (B) and only one sample for α-SMA (C, far right). Podoplanin (G) also has high levels of 
positive expression. Negative expression can be seen in GFAP (D) and three of four samples in CD38 (E).  
MFI was also calculated to quantify the data that are represented in the histograms (Figure 3.5) 
(Figure 3.6).  
3.4 Population shift from single positive cells into double positive population shown with 
CD146+ and OVA+. Interestingly, across different passages there was a strong population shift 
from single positive cells into double positive expression for both CD146 and OVA, two LSEC 
markers (Figure 3.7). This was seen in different human samples when comparing passage 5, 7, 
and 9. The two depictions show one sample from a patient who had not undergone chemotherapy 
treatment (Figure 3.7, A) and one sample from a patient who has undergone chemotherapy 
(Figure 3.7, B). Respective contour plots for each sample are shown across all three passages 
(Figure 3.7). 
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Figure 3.6 Mean Fluorescence Intensity (MFI) of Hepatic Stellate Cells. Statistical data of figure 3.5 are shown 
with the MFI data. MFI is quantified to show which marker is expressed and to what degree. All markers were tested 
with an unstained control and an isotype control (grey). Each bar graph includes isotype control, passage 5 (red), 
passage 7 (cyan), and passage 9 (green). Positive expression is seen in HSC activation marker CD14 (A), intracellular 
stain for Vimentin (B), and podoplanin (F). Negative expression is seen in CD38 (D), very low expression is seen in 
Desmin (E).  
CD146 and OVA are two very strong markers for the murine LSEC population which is why we 
investigated both of them in human LSECs. The population shift becomes very interesting when 
looking at passage 5 for both samples which show a double positive population being less than 
25% of the total cell count for both samples. In later passages the total population that is double 
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positive increases up to 60% by passage 9 (Figure 3.7). MFI for OVA, CD146, and isotype also 
were investigated. The MFI for OVA did not shift considerably over the three passages (Figure 
3.8 A and B, left) for either sample: 8/17/16 (Figure 3.8, A) or 12/21/16 (Figure 3.8, B). However, 
CD146 expression changed considerably from passage 5 to passage 9 there was a dramatic increase 
across passages (Figure 3.8 A and B, right). Frequency of the double positive population changed 
over time, starting at less than 25% of the total population and becoming 60% of the total 
population (Figure 3.8, C). 
A
B
Figure 3.7 Population shift in CD146+ OVA+ cells across passages. Representation of contour plots show dramatic shifts in cellular 
populations for CD146+ OVA+ cells across different passages that include passage 5, passage 7, and passage 9 for human liver sample 
digested on 8/17/16 (A, left to right). The cellular population shift between a low population of CD146+ OVA+ for passage 5 
increases in different samples as well, this can be represented in human liver sample 12-21-16 (B, left to right). The shift in population 
can be seen in samples that have either not undergone chemotherapy treatment and those that have (A and B). 
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Figure 3.8: In order to fully understand how the population has shifted, MFI from figure 3.7 was calculated for each sample, 
for OVA, CD146 and CD146 expression compared to Isotype (A and B). 8/17/16 (A). 12/21/16 (B).  While the OVA population 
didn’t increase as dramatically as expected (A and B left), CD146 MFI increased drastically across passage numbers (A and B, 
right). The total number of cells that presented with this double positive population increased across passage numbers and is 
shown as a frequency of total bar graph (C). 
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Chapter 4: Discussion  
In this thesis, we investigated two subsets of human liver stromal cells, Liver Sinusoidal 
Endothelial Cells and Hepatic Stellate Cells. This was done in a number of ways: we analyzed 
growth rate, and extracellular markers and intracellular markers for LSEC and HSC populations. 
These criteria were examined and tested across different passages of human liver samples in vitro 
to gain insight into the biology of human LSEC and HSC stromal cells. We addressed the following 
questions: 1) what are the different cellular markers on these cells, 2) how well are these markers 
expressed, and 3) do stromal cells maintain these cellular markers over the course of cellular 
expansion? We were able to compare markers for each of the two subsets in order to determine 
the differences between them at different passages and between the different samples acquired. 
This information provides a better understanding of the two cellular subsets and helps identify 
markers present on these human cells in culture. Previous work has been done mainly in mice. 
Cellular markers that were tested previously in mice include CD54, CD106, VAP, LSIGN, 
Mannose Receptors, Scavenger Receptors, CD80, CD86, CD40, CD4, CD11c (Knolle, 2001). We 
investigated whether markers expressed on mouse liver stromal cells were similarly expressed on 
human liver stromal cell populations. 
 Our studies show that human liver stromal cells are stable and can withstand many 
passages irrespective of patient diagnosis, age, sex, or therapy with chemotherapy or radiation. We 
had originally hypothesized that stromal cells derived from different diseases would have different 
growth patterns, but this was not the case. Our samples were from patients that did not have HIV, 
HPV, HCV, Hepatitis, Inflammatory Liver Disease, Non-Alcoholic Fatty Liver Disease, or other 
inflammatory liver diseases. Most samples were from patients with a diagnosis of cancer. A 
considerable number of our samples (7) were from patients treated with a chemotherapeutic drug 
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and we tracked which samples had been treated and which had not. Through these comparisons, 
we found no distinguishable difference between those from patients that had been through 
chemotherapeutic treatment and those that had not. Age and sex was another parameter that was 
explored but did not have any profound differences amongst the different samples. 
In addition to sample variability and cellular growth rate, cellular markers were identified 
in the human samples that were expanded. The goal of these studies was to understand how stable 
the cellular markers, both intracellular and on the cell surface, are and if possibly the cells lose the 
markers during progressive passages. We found that specific cellular markers can be seen on 
stromal cells across many passages and also remain stable. The most prominent marker that was a 
positive identifier for LSECs was the surface marker CD146 which is expressed on epithelial cells. 
CD146 main function is maintenance of the integrity of the epithelial junctions which explains 
why it is seen on LSECs and not on HSC (Limmer, 2000). These LSECs were also CD45 negative 
which was to be expected as LSECs do not express CD45; this was used as a control to ensure 
there weren’t any leukocytes in our population and give further proof that our sample had 
undergone purification and selection for stromal cells (Connolly, 2010). CD146+ signal was found 
in every sample tested regardless of passage number. This was a very important result because this 
was our first evidence that there was a clear marker that remained stable over many passages in 
human LSECs. However, there CD146 expression levels changed over the course of passaging 
and it is unclear why. For example, in sample 8-17-16 and 1-19-16 CD146 expression decreased 
over passages while in 10-20-16 and 12-21-16, CD146 expression increased across passages. 
These differences did not correlate with patient treatment history.  
CD146 was not the only marker identified in human LSECs. Scavenger receptors are 
another highly selective feature of LSECs, specific to this cell type compared to HSCs. The ability 
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of the scavenger receptors on LSECs to uptake antigen is highly characteristic of LSECs because 
of their endocytic abilities, as demonstrated by the uptake of OVA in the treated sample. Similar 
to the changes in CD146 expression, there was a shift in uptake of OVA in the cell lines that was 
not consistent across samples. It was incredibly important to include CD146 and OVA in every 
experiment in order to have an LSEC identifier and exclude other cell types including leukocytes.  
 Worth noting, CD106 expression on LSECs has been questioned in the field where some 
studies claim LSECs do not express CD106 (Elvevold, 2007), while others claim there is 
expression (Karrar, 2007). We found some CD106 expression on human LSECs. Our histograms 
showed CD106 expression over time and MFI score and a positive signal amongst our samples, 
CD146 and scavenger receptors are not the only positive results seen; CD54, MHC I, CD32, CD80 
were also expressed, as shown both in histograms and MFI score. Not all markers tested were 
positive expression though. We also investigated CD31, CD206, and CD50 (ICAM-3) but these 
showed either very low expression or, a negative signal.  
CD45 was used for leukocyte exclusion in these experiments. After many experiments 
where CD45 was not detected, CD45 was later taken out of later experiments in order to open up 
the UV laser for the HSC experiments. This was important because it allowed for a dump channel 
(channel that could detect fluorescence without antibody) to be created in the violet laser in order 
to test fluorescence of vitamin A by the HSCs. Vitamin A glows excessively in the UV channel 
and is seen in the violet laser and is a positive identifier of HSCs (Kubota, 2007). We unfortunately, 
did not get signal for vitamin A in our studies. This could be due to many different things; we 
speculated that the cells may lose the capacity to maintain vitamin A storage in culture over many 
passages because we did not supplement Vitamin A in the media and the vitamin A simply became 
depleted. Based on studies of mouse HSCs we tested whether human HSCs expressed Vimentin, 
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osteopontin, α-SMA, and Desmin (Chagraoui, 2003). Other markers of interest were CD14 which 
is expressed on activated stellate cells, CD38, GFAP and podoplanin. It is known that α-SMA is 
a highly reliable marker for HSCs because it is absent from other liver resident cells. Interestingly, 
if HSCs are activated, α-SMA expression is increased which will lead to an increase in fibrosis in 
the environment (Morini, 2005). The expression of α-SMA is not only specific for identification 
of HSC but also important in understating the progression of fibrosis. GFAP is another 
characteristic marker of HSC that is typically quiescent in cells; if the cells lose expression of 
GFAP they become activated which starts the process of collagen production thus leading to 
fibrosis. We did not find any level GFAP expression, but we did find positive expression for α-
SMA in two of the samples that steadily decreased across passage numbers. In regards to α-SMA, 
the two samples that were positive, both were very different; one sample was a patient treated with 
chemotherapy and one not. There isn’t clear understanding why some were positive and others 
were not; it may be that over the course of many passages the cells start to lose expression or that 
simply that each sample is very different. Low levels of Desmin were seen in each and this was 
less than we had anticipated. However, high expression levels of CD14, Vimentin, and Podoplanin 
were quantified in all HSCs samples when comparing both the MFI values and the representative 
histograms. Further work with stimulation assays such as cytokine production, stimulation with 
LPS, and co-culture experiments is necessary to understand how expression of these markers may 
change over the course of multiple passage numbers.  
The findings in this thesis show the variability of the stromal cell subsets and their 
durability over time. We have identified specific cellular markers to use in future studies of LSECs 
and HSCs. These markers will be useful for many applications such as cellular sorting of primary 
human tissue samples, transcriptional profiling using single cell RNA sequencing, purification of 
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LSEC or HSC for co-stimulatory assays, cytokine production assays, and many other biological 
assays. The work provided in this thesis lays the groundwork for future studies of Liver Sinusoidal 
Endothelial Cells and Hepatic Stellate Cells.  
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Chapter 5: Limitations and Perspectives 
Our data have provided a quantifiable understanding of stromal cell growth rate. While we 
have found an average amount of time for the cells to reach confluence across different passages, 
it cannot be definitively stated how long it will take for each cell line to grow and it cannot be 
normalized for each subsequent sample that may be acquired. These cells are different for each 
sample which makes sense because of the different patient diagnoses. It is valuable to have an 
understanding of how long it will take from stage zero until passage 5 for example, because these 
cells do grow relatively slowly up until the first passage. Another variability in growth is that some 
cell lines had to go through a second digestion, or some needed to be left in the digestion mixture 
longer than others due to the toughness of the sample; these differences affect how quickly the 
cells grow. While it was not a normal procedure for the samples to go through a second digestion, 
it was not uncommon for large samples to undergo a second digestion due to size of the sample. 
The larger samples needed a second digestion. 
Sample variables involving time impacted our studies. We tried our absolute best to acquire 
and digest the sample as soon as possible in order to limit the amount of time the whole tissue sat 
either on the bench top post-surgical resection, in the refrigerator, on ice, etc. for fear of having 
cells die. We tried to be conscientious about the whole process in order to have our samples be the 
healthiest possible and keep the cells in their best possible condition in the hopes that this would 
lead to healthy growth in culture.  
While our results point to what markers are stable, a major limiting factor was the passage 
at which cells could be tested. We did not want to use all of our earliest passage number samples 
for marker studies, because when those passages are depleted, we cannot get them back. We 
anticipate that the earliest passage numbers, (P0 and P1) may present with different expression of 
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markers but we did not use those cells for fear of depleting our entire sample. Expansion of frozen 
cells was carefully calculated as to which passage number could be used when thawing cells for 
different liver samples. The earliest passage number that we could freeze was passage 3, but not 
every cell line grew enough to be able to freeze cells at this specific cell passage; others started to 
be frozen at passage 4. Growth and confluence of the cells was a deciding factor in how to move 
forward with experiments.  
Our experiments give us insight into which markers are able to withstand trypsin and many 
cellular passage numbers but that do not answer all of our questions. A remaining question is at 
what passage number do the markers start to lose expression? Some experiments were done at 
passage number 12 and tested against other early passage numbers which showed positive signal 
but also quite a bit more background noise which could have been due to more broken, dead or 
dying cells in the media. The longest cultured cells became very sticky and were difficult to pellet 
and resuspended.  
While there were definitely areas of the project that proved challenging, future studies are 
extremely exciting. The identification of marker that are present on these stromal cells will allow 
us to do many future experiments including the use of single cell RNA sequencing to perform 
transcriptional profiling. Understanding when human samples in culture lose vitamin A storage 
would be beneficial as well because this could provide another means to sort out cells. We by no 
means explored a comprehensive list of markers; there are other that could be investigated and 
tested in vitro. By having specific markers such as CD146 for LSECs and α-SMA for HSCs, 
cellular sorting of these defined populations will be possible. When purified samples are then 
acquired using these markers many other assays may be done to understand the functions of these 
cells including stimulation of the cells and co-culture experiments.  
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Concluding statements:  
In this thesis we sought to understand human liver stromal cells in different capacities 
including LSEC marker identification, HSC marker identification, and cellular growth rate. Our 
aim was to understand what changes occur in cellular expression of markers and cellular growth 
rate. Experiments revealed markers that are positive for LSECs such as CD146, scavenger 
receptors, and CD106; whereas positive expression on HSCs was also seen with Vimentin, α-
SMA, and Podoplanin. Identification of markers that are negative such as CD50, MHC II for 
LSECs, and GFAP for HSC proved to be just as valuable in that negative markers have given us 
an understanding of what not to use as a selective marker for these cells. While it was known in 
mice that Vitamin A glows when excited by the UV laser, we did not find this to be true in our 
experiments with human stromal cells. In addition to testing cellular markers, we polished an 
established protocol to maintain human stromal cells in culture for over 14 passages which then 
gave us insight into how these samples grow. By understanding the growth capacities of these cells 
we were able to optimize the amount of cells acquired. This project helped us learn about human 
LSECs and HSCs by using published knowledge from mice and translating that work into studies 
with human samples. Our results provide a foundation for future studies with human liver stromal 
cells.   
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Table 1.3 Human tissue sample data and observation allow for characterization of disease and origin of sample. 
The quantification of data that is acquired from these samples allows for experimental design to be shifted based on 
populations that would be selected for; i.e. male vs female experiments, similar diagnosis, chemotherapy treatment 
and other options. *patient underwent chemotherapy **patient underwent radiation treatment 
 
